[Cape Town, South Africa | February 10, 2026] As global demand for transition and technology minerals surges, countries in the Global South must redefine their [Cape Town, South Africa | February 10, 2026] As global demand for transition and technology minerals surges, countries in the Global South must redefine their

New African Mineral Value Chain Centre Debuts At Mining Indaba

2026/02/10 14:46
3 min read

[Cape Town, South Africa | February 10, 2026] As global demand for transition and technology minerals surges, countries in the Global South must redefine their mineral assets not just through the lens of international supply chains, but through domestic development imperatives.

The Linkage-Based Criticality Matrix (LBCM™), developed by the Centre for African Mineral Value Chains (CAMVaC)—the policy research arm of ESG Frontiers—provides policymakers with a robust tool to prioritise strategies and investments aligned with local realities and long-term resilience.

South Africa’s Critical Minerals and Metals Strategy (released May 2025) is a bold step forward, classifying minerals like manganese as high-critical and emphasising job creation, industrial advancement, and national security. Yet, like many regional frameworks, it leans on export value and global demand without fully quantifying how minerals anchor domestic jobs, infrastructure, knowledge flows, and institutional capacity.

In collaboration with labour unions, researchers, and policy actors, ESG Frontiers and CAMVaC are advancing the LBCM™ as a complementary diagnostic. Grounded in producer economies—especially in the Global South—this tool assesses criticality through linkages: backward inputs, forward beneficiation, knowledge/skills, innovation, horizontal spillovers, and geopolitical leverage.

“This is not about replacing national strategies,” Nedohe emphasises. “It’s about completing them. The LBCM  helps us ask: If we remove a mineral, what collapses? What must be rebuilt? And who bears the cost?”

Coal miningCoal mining. Freepik

In applying the LBCM at CAMVaC, coal remains South Africa’s most critical mineral today due to its extensive linkages: powering ~80% of electricity, underpinning Sasol’s coal-to-liquids process (supplying ~30% of national liquid fuels), and sustaining ~80,000–110,000 direct mining jobs with vast downstream multipliers.

Yet, with accelerating global net-zero commitments and a projected ~50% decline in thermal coal exports by 2035, coal’s criticality is eroding. This inflection point elevates manganese as the emerging successor: its forward linkages in LMFP batteries could unlock R50+ billion in value addition, 50,000+ new jobs, Mintek-led innovation spillovers, and geopolitical leverage to diversify from China’s processing dominance. The LBCM quantifies this shift, positioning manganese as the strategic bridge to green industrialisation.

The LBCM is statistically robust, tested through Monte Carlo simulations across more than 30 sub-indicators and 7–8 dimensions. This rigour ensures replicability and underpins the development of a Python-based dashboard for policymakers to interact with the diagnostic in real time.

Soft-launched in Cape Town on the sidelines of Africa’s largest mining event, CAMVaC is grateful for the support of stakeholders during the research process—especially the Minerals Council South Africa, Mintek, and regional DMRE offices. These partners will be engaged further to ensure that the next iteration of the CMS-SA is scientifically benchmarked amongst the best in the world.

“We need to stop borrowing frameworks that were never designed for us,” says Nedohe. “The LBCM is one way to start writing our own.”

Further stakeholder engagements with labour, government, and development finance institutions are planned for early 2026 to refine and operationalise this approach.

As part of the Cape Town soft‑launch, CAMVaC also reached out to neighbouring states—including Namibia, Zimbabwe, and partners across the broader Southern region—to gauge appetite and begin harmonising approaches to mineral criticality in the Global South.

Market Opportunity
Notcoin Logo
Notcoin Price(NOT)
$0,0003856
$0,0003856$0,0003856
-%3,43
USD
Notcoin (NOT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26